Changes in Cytokines Status of Patients with Recurrent Pulmonary Tuberculosis Receiving Chemotherapy
Published on: 2018-05-20
Background and objective Select cytokines in patients with recurrent TB receiving anti-TB chemotherapy were compared to the levels in healthy individuals in order to assess the balance between inflammatory and anti-inflammatory responses. Materials and methods Cytokines, IL-2, IL-4, IL-8, IL-10 and IFN-γ, were examined by quantitative ELISA (pg/L) in patients with recurrent TB (1st group; N=100) and healthy individuals (2nd group; N=30). All patients received standard TB drugs: Isoniazid (0.3 g); Rifampicin (0.6 g); Pyrazinamide (2 g); Ethambutol (1.2 g) and/or Streptomycin (1 g). Results At baseline the 1st group had serum levels of IL-2 (39.44±0.71); IL-4 (9.55±0.24); IL-8 (21.14±0.32); IL-10 (40.04±0.74) and IFN-γ (106.20±0.67); 2nd group had IL-2 (21.60±0.80); IL-4 (29.99±1.27); IL-8 (9.96±0.62); IL-10 (50.25±1.26); IFN-γ (63.82±2.27). After 2 months, there was a significant decrease in pro-inflammatory cytokine levels in the 1st (IL-2: 29.59±0.55; IL-8: 18.22±0.22; IFN-γ: 71.14±1.21). Conversely, IL-4 increased in 1st to 16.68±0.44 and IL-10 – 48.53±0.87 (p<0.05). Conclusion Prior to the study initiation patients with TB had higher IL-2, IL-8, IFN-γ and lower IL-10 and IL-4 content than healthy controls. Two-month chemotherapy produced significant reduction in pro-inflammatory cytokines and increase in anti-inflammatory IL-10 and IL-4, with levels approaching those of healthy controls. Thus, TB drugs appear to have the anti-inflammatory effect in TB patients, which was predictive of positive clinical outcome.